Several inhibitors of KIF11, which is upregulated in a wide range of cancers (Oncomine, http://www.oncomine.org), are already in clinical trials as anti-cancer drugs [9], and a KIF20A inhibitor has recently been identified [46]. Here, KIF20A is linked to cancer.